A clinician fielding a patient's question about "GLP-3 peptide therapy" for metabolic syndrome will not find a corresponding entry in PubMed, ClinicalTrials.gov, or any major endocrinology reference. The receptor does not appear in the incretin literature alongside GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), or glucagon receptor pathways. What the patient is very likely encountering is marketing terminology from research-chemical vendors or informal online forums that have applied the label loosely to multi-agonist peptides — compounds that combine GLP-1 receptor activity with GIP or glucagon receptor activity in a single molecule.
This distinction matters clinically. Metabolic syndrome — defined by ATP III and harmonized criteria as three or more of: elevated waist circumference, elevated triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose — is a well-studied population in incretin-based trials, but the compounds with actual trial data are semaglutide (a GLP-1 receptor agonist), tirzepatide (a dual GLP-1/GIP receptor agonist), and retatrutide (a triple GLP-1/GIP/glucagon receptor agonist). This analysis compares what the Phase 2 and Phase 3 data actually show for these three agents, since that is the evidence base underlying most "GLP-3" search queries.
Terminology: Why "GLP-3" Does Not Correspond to a Known Target
The incretin system recognized in peer-reviewed pharmacology includes two primary hormones: GLP-1, secreted by intestinal L-cells, and GIP, secreted by K-cells. A third relevant peptide in current multi-agonist drug design is glucagon itself, acting through the glucagon receptor to increase energy expenditure and hepatic glucose output in a way that, combined with GLP-1/GIP agonism, appears to enhance weight loss in early trial data. None of these three pathways are labeled "GLP-3" in any indexed publication.
Some vendor and forum sources appear to have generated the term informally, either as a marketing shorthand implying a "next-generation" compound beyond GLP-1, or through confusion with the numbering of trial programs and dose-ranging studies. Neither explanation reflects an actual distinct receptor or hormone class recognized in the endocrinology literature as of this writing.
For clinical and research purposes, the relevant comparison set is GLP-1 receptor monotherapy (semaglutide), dual GLP-1/GIP agonism (tirzepatide), and triple GLP-1/GIP/glucagon agonism (retatrutide). This article uses those three compounds as the basis for comparative analysis, since that is the actual evidence base available to inform decisions about incretin-based therapy in metabolic syndrome.
Metabolic Syndrome as a Trial Population
Most Phase 3 obesity and diabetes trials do not enroll strictly on a formal metabolic syndrome diagnosis; they enroll on BMI thresholds (typically ≥27 kg/m² with a comorbidity, or ≥30 kg/m² without) plus type 2 diabetes status, and report metabolic syndrome components as secondary or exploratory endpoints. This is an important methodological detail — cross-trial comparisons are working from populations that overlap heavily with, but are not identical to, a formally diagnosed metabolic syndrome cohort.
STEP 1 (NCT03548935) enrolled adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity, excluding diabetes. SURMOUNT-1 (NCT04184622) used similar criteria. The retatrutide Phase 2 trial (NCT04881413) enrolled adults with BMI ≥30, or ≥27 with a comorbidity, without diabetes as well. This means the trial populations reviewed here are enriched for, but not exclusively composed of, patients meeting formal metabolic syndrome criteria.
Where trials do report metabolic syndrome components specifically — waist circumference, lipid panels, blood pressure, fasting glucose — those secondary endpoints are the most directly relevant data points for a metabolic syndrome-focused evaluation, and are addressed by compound in the sections below.
Semaglutide: GLP-1 Receptor Agonist Monotherapy Data
STEP 1 (Wilding et al., NEJM 2021, PMID 33567185) randomized 1,961 adults to once-weekly subcutaneous semaglutide 2.4 mg or placebo over 68 weeks. Mean weight change was -14.9% in the semaglutide arm versus -2.4% with placebo, a between-group difference of -12.4 percentage points (95% CI -13.4 to -11.5, p<0.001). Discontinuation due to adverse events occurred in 7% of the semaglutide group.
Beyond weight, STEP 1 reported improvement in waist circumference (-13.5 cm vs -4.1 cm), systolic blood pressure, and lipid parameters as secondary endpoints — the components most directly relevant to a metabolic syndrome assessment. These changes tracked closely with degree of weight loss rather than representing an independent metabolic effect distinct from the weight change itself.
The SELECT trial (Lincoff et al., NEJM 2023, PMID 37952131) extended the evidence base to hard cardiovascular outcomes in a population with pre-existing cardiovascular disease and overweight or obesity without diabetes (n=17,604). Over a median follow-up of 39.8 months, semaglutide reduced major adverse cardiovascular events by 20% (HR 0.80, 95% CI 0.72-0.90). This is the strongest outcomes-level evidence currently available for any agent in this comparison set, and it matters for metabolic syndrome patients specifically because cardiovascular risk reduction — not just weight change — is the eventual clinical target of treating the syndrome.
Tirzepatide: Dual GLP-1/GIP Receptor Agonist Data
SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) randomized 2,539 adults without diabetes to tirzepatide 5 mg, 10 mg, 15 mg, or placebo over 72 weeks. Mean weight change was -15.0%, -19.5%, and -20.9% across ascending doses, versus -3.1% with placebo. At the 15 mg dose, 57% of participants achieved ≥20% weight loss, compared with 3% on placebo.
For metabolic syndrome-relevant secondary endpoints, SURMOUNT-1 reported reductions in waist circumference, triglycerides, and blood pressure that scaled with dose, along with improvement in HDL cholesterol at higher doses. Adverse events were predominantly gastrointestinal — nausea (up to 31% at the highest dose), diarrhea, and constipation — with discontinuation due to adverse events ranging from 4.3% to 7.1% across dose groups.
SURPASS-4 (NCT03730662), conducted in patients with type 2 diabetes and high cardiovascular risk, compared tirzepatide against insulin glargine and found superior glycemic control (HbA1c reductions of 2.1-2.4 percentage points versus 1.4 with insulin glargine) along with weight loss rather than weight gain, a clinically relevant distinction for a population where insulin therapy commonly drives further weight gain and worsens metabolic syndrome components.
Retatrutide: Triple GLP-1/GIP/Glucagon Receptor Agonist Data
The retatrutide Phase 2 trial (Jastreboff et al., NEJM 2023, PMID 37366315, NCT04881413) randomized 338 adults without diabetes to retatrutide across a dose range (1 mg to 12 mg) or placebo over 48 weeks. At the highest dose, mean weight change reached -24.2%, versus -2.1% with placebo — the largest effect size reported to date among this compound class, though from a substantially smaller and earlier-phase trial than STEP 1 or SURMOUNT-1.
Secondary metabolic findings included larger reductions in triglycerides and greater improvements in measures of insulin sensitivity compared with cross-trial figures for GLP-1 monotherapy, plausibly attributable to the added glucagon receptor agonism, which increases hepatic fatty acid oxidation and energy expenditure independent of appetite suppression. These findings are physiologically plausible but have not been confirmed in a head-to-head randomized comparison against tirzepatide or semaglutide.
Gastrointestinal adverse events were common (nausea in up to 58% of the highest-dose group), and heart rate increases were observed and attributed to glucagon receptor activity — a tolerability signal specific to the triple-agonist mechanism that warrants monitoring in any patient considered for this drug class as trials progress. As of this writing, retatrutide remains investigational with no completed Phase 3 outcomes trial published.
Cross-Trial Comparison: Effect Size, Attrition, and What the Numbers Mean
Lining up primary endpoints across these three programs, weight loss magnitude increases roughly in proportion to the number of receptor targets engaged: semaglutide (GLP-1 only) at -14.9%, tirzepatide (GLP-1/GIP) at -20.9%, and retatrutide (GLP-1/GIP/glucagon) at -24.2% at their respective top studied doses. This is a consistent pattern across independent trials, though it is a cross-trial comparison, not a head-to-head randomized comparison, and populations, trial duration, and dose-titration schedules differ.
Attrition and discontinuation rates provide a useful cross-check on tolerability claims. STEP 1 reported 7% discontinuation due to adverse events; SURMOUNT-1 ranged 4.3-7.1% by dose; the retatrutide Phase 2 trial, being smaller and shorter in duration with faster titration in some arms, reported higher rates of GI adverse events but comparable overall trial completion.
For a clinician evaluating options in a metabolic syndrome patient specifically, the practical read is that effect size on weight and its downstream metabolic components trends upward with additional receptor engagement, but so does the burden of gastrointestinal tolerability issues during titration, and the strength of the supporting evidence trends the opposite direction — semaglutide has the most mature dataset including hard cardiovascular outcomes, tirzepatide has robust Phase 3 data without a completed CVOT publication at the same scale as SELECT, and retatrutide remains Phase 2 only.
Effects on Individual Metabolic Syndrome Components
Waist circumference reduction tracks closely with total weight loss across all three agents, with STEP 1 reporting -13.5 cm, SURMOUNT-1 reporting reductions in the -14 to -18 cm range by dose, and the retatrutide trial reporting the largest reductions consistent with its larger weight-loss effect size.
Triglyceride reduction and HDL improvement were reported as secondary endpoints across all three programs, generally following the same dose-dependent pattern, though absolute percentage changes vary by trial and are not consistently reported using identical methodology, which limits precise cross-trial numeric comparison.
Blood pressure reductions in the range of 4-6 mmHg systolic were reported across the GLP-1 and dual-agonist trials, a magnitude comparable to what would be expected from weight loss of similar degree in the general hypertension literature, suggesting the effect is substantially mediated by weight change rather than a distinct antihypertensive mechanism.
Glycemic parameters, even in non-diabetic trial populations, showed improvement in fasting glucose and insulin sensitivity markers, with the largest relative improvements reported in the retatrutide trial, plausibly reflecting the added glucagon receptor contribution to hepatic glucose handling alongside incretin-driven insulin secretion.
Safety, Monitoring, and Population-Specific Considerations
Across all three compound classes, gastrointestinal adverse events are the dominant tolerability issue, with nausea, vomiting, diarrhea, and constipation reported at rates that generally increase with dose and speed of titration. Slower titration schedules used in later trial protocols and clinical prescribing appear to reduce, though not eliminate, these events.
Retatrutide's additional glucagon receptor agonism introduces a heart rate signal not seen to the same degree with GLP-1 or dual GLP-1/GIP agents, which warrants specific attention in patients with pre-existing arrhythmia or significant cardiovascular disease pending further Phase 3 data. Gallbladder-related events (cholelithiasis, cholecystitis) have been reported across the GLP-1 receptor agonist class more broadly and are worth monitoring for, particularly with rapid weight loss.
None of the three agents discussed here have trial data specifically powered for a formally diagnosed metabolic syndrome population as the primary enrollment criterion, which is a genuine gap in the literature. Current evidence is inferred from overweight/obesity trials with metabolic syndrome components reported as secondary endpoints, not from trials designed around metabolic syndrome diagnostic criteria as the primary study population.
What Remains Unclear
No published head-to-head randomized trial directly compares semaglutide, tirzepatide, and retatrutide in the same study using identical dosing, titration, and endpoint definitions. Cross-trial comparisons, including the figures summarized above, carry inherent limitations from differing populations, trial durations, and measurement methodology.
Retatrutide's Phase 3 program had not published outcomes data at the time of this analysis, meaning its comparative safety and efficacy profile relative to tirzepatide and semaglutide remains provisional. Long-term cardiovascular outcomes data — the kind SELECT provided for semaglutide — do not yet exist for tirzepatide or retatrutide at the same evidentiary scale.
Given the absence of any recognized "GLP-3" target in the literature, clinicians encountering patient questions using that term should clarify which specific compound and mechanism the patient is actually asking about before making any treatment-related discussion, since research-chemical vendors marketing peptides under informal or nonstandard names may not reflect verified purity, dosing, or even the receptor activity claimed.
Clinicians and researchers evaluating incretin-based therapy for a patient meeting metabolic syndrome criteria have a genuine and growing evidence base to draw from — it is simply organized around GLP-1, GIP, and glucagon receptor pharmacology rather than any distinct "GLP-3" system, and treatment decisions should be grounded in the specific trial data for the specific compound under consideration.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.